glp-1 in type 2 diabetes Clinical Focus on Agonists Mellitus Targeting GLP-1, GIP & GCG

Data show that in adult patients with type 2 diabetes with increased cardiovascular (CV) risk, compared with titrated insulin glargine, all three doses of tirzepatide show superiority in reducing blood sugar and body weight: treatment for 52 weeks, with curative effect Estimation (efficacy estimand) statistical analysis method, the highest dose of tirzepatide (15 mg, once a week) reduces blood glucose level (A1C) from baseline by 2.58%, and weight from baseline by 11.7 kg (25.8 pounds, 13.0%), and titration Insulin glargine reduced A1C from baseline by 1.44% and body weight increased by 1.9 kg (4.2 lbs, 2.2%) from baseline

Clinical trials showed an average weight loss of 15% of body weight over 68 weeks when combined with lifestyle interventions

Instead, experts believe that the significant weight loss caused by GLP-1 medications, like Mounjaro and Wegovy, triggers a condition called telogen effluvium

doi: 10.1371/journal.pone.0087716 10 TseliosKKoumarasCUrowitzMBGladmanDD

They also found that there was a significant association between rosacea and LDL cholesterol in the bloodstream

The label is marketing